Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

A new HIV prevention shot, approved by the FDA and taken just twice a year, could transform global care, but experts warn shrinking health budgets may limit access in high-risk areas.

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a powerful and convenient new way to ward off infection in a wide range of ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...